3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
53
Neoplasm Metastasis
16
Carcinoma, Non-Small-Cell Lung
10
Neoplasms
7
Brain Neoplasms
5
Prostatic Neoplasms
3
Ovarian Neoplasms
3
Neoplasms by Site
3
Melanoma
3
Glioma
3
Endometrial Neoplasms
3
Colorectal Neoplasms
3
Breast Diseases
3
Sarcoma, Ewing
2
Recurrence
2
Pancreatic Neoplasms
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Lymphoma
2
Glioblastoma
2
Advanced Cancer
2
Uterine Cervical Neoplasms
1
Urogenital Neoplasms
1
Unilateral Breast Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Spinal Cord Neoplasms
1
Solid Tumor, Adult
1
Sarcoma
1
Rhabdomyosarcoma
1
Interventions
Fulvestrant
9
Alpelisib
6
Letrozole
4
serabelisib
3
ribociclib
3
palbociclib
3
duvelisib
3
berzosertib
3
Paclitaxel
3
PX-866
3
Cetuximab
3
sapanisertib
2
pembrolizumab
2
parsaclisib
2
binimetinib
2
Topotecan
2
NVP-BKM120
2
Irinotecan
2
Gemcitabine
2
venetoclax
1
tipifarnib
1
talazoparib
1
sotorasib
1
ruxolitinib
1
olaparib
1
obinutuzumab
1
niraparib
1
lorlatinib
1
liposomal doxorubicin
1
gedatolisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Hereditary Sensory and Autonomic Neuropathies
×
abemaciclib
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled